OHM1 

OHM1 is an analog of HIF1α CTAD that inhibits its binding with p300/CBP. OHM1 targets CH1 domain with an affinity of 0.53 μM^[1].

OHM1 (1-20 μM; 24 h) results in a dose-dependent reduction in the HIF promoter activity, and reduces the level of HIF1α transcriptional activity under hypoxia to that observed under normoxia at 20 μM in MDA-MB-231 cells^[1].
OHM1 down-regulates hypoxia-inducible gene expression^[1].
OHM1 (10 μM) down-regulates multiple genes implicated in angiogenesis, apoptosis, cell proliferation, and invasion, along with several cancer-specific markers in the A549 non-small-cell lung cancer cell line^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

OHM1 (15 mg/kg; i.p.; every other day for 15 injections) reduces MDA-MB-231 tumor volume in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

494.63

C₂₄H₄₂N₆O₅

1450995-09-1

O=C(N)[C@@H](N1C([C@H](C)N(C([C@@H](N2C([C@H](CC(C)C)NCC2)=O)CC(C)C)=O)CC1)=O)CCC(N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lao BB, et al. In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics. Proc Natl Acad Sci U S A. 2014 May 27;111(21):7531-6.  [Content Brief]